Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- National trends in ambulatory oral anticoagulant use.Am J Med. 2015; 128: 1300-1305.e2
- Trends in anticoagulant prescribing: a review of local policies in English primary care.BMC Health Serv Res. 2020; 20: 1-8
- New trends in anticoagulation therapy.Surg Clin North Am. 2018; 98: 219-238
- Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients.J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2017; 6e004517https://doi.org/10.1161/JAHA.116.004517
- Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications.Circulation. 2011; 123: 1108-1115
- Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores.BMJ. 2014; 349: g4606https://doi.org/10.1136/bmj.g4606
- Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.Lancet Gastroenterol Hepatol. 2018; 3: 231-241
- Peptic-ulcer disease.Lancet. 2002; 360: 933-941
- Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies.Thromb Haemost. 2013; 110: 205-212
- Gastrointestinal bleeding with oral anticoagulation: understanding the scope of the problem.Clin Gastroenterol Hepatol. 2017; 15: 691-693
- Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: Endoscopic findings, clinical management and outcome.World J Gastroenterol. 2005; 11: 1365-1368
- Upper gastrointestinal bleeding in the setting of excessive warfarin anticoagulation: Risk factors, and clinical outcome.Cor Vasa. 2017; 59: e128-e133
Kurlander J, Fisher A, Gonzalez J, et al. Review protocol: The effect of anti-secretory agents on upper gastrointestinal bleeding risk for patients using oral anticoagulants: a systematic review. Available at: https://www-crd-york-ac-uk.proxy.lib.umich.edu/prospero/display_record.php?ID=CRD42020136610. Accessed January 14, 2021.
Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed May 15, 2019.
- RoB 2: a revised tool for assessing risk of bias in randomised trials.BMJ. 2019; 366: l4898https://doi.org/10.1136/bmj.l4898
- Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants.Clin Gastroenterol Hepatol. 2015; 13: 906-912.e2
Lee, SR., Kwon, S., Choi, EK. et al. Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding. Cardiovasc Drugs Ther (2021). https://doi.org/10.1007/s10557-021-07170-6. Accessed December 15, 2021.
- Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial.Gastroenterology. 2019; 157: 403-412.e5
Confidence Interval for a Rate Difference. Available at: https://sphweb.bumc.bu.edu/otlt/MPH-Modules/PH717-QuantCore/PH717_ ComparingFrequencies/PH717_ComparingFrequencies12.html. Accessed July 12, 2021.
- Cochrane Handbook for Systematic Reviews of Interventions.2nd ed. Wiley-Blackwell, Hoboken, NJ2019: 1-728
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.BMJ. 2021; 372: n71
- Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy.Gastroenterology. 2011; 141: 71-79
- Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding.JAMA. 2018; 320: 2221-2230
- Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding.Gastroenterology. 2016; 151 (e10): 1105-1112
- Difference between the upper and the lower gastrointestinal bleeding in patients taking nonvitamin K oral anticoagulants.BioMed Res Int. 2018; 20187123607
Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC Expert Consensus Decision Pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 77(5):629-658. 10.1016/j.jacc.2020.09.011.
- Guidelines for prevention of NSAID-related ulcer complications.Am J Gastroenterol. 2009; 104: 728-738
- Deprescribing proton pump inhibitors: overcoming resistance.JAMA Intern Med. 2020; 180: 571-573https://doi.org/10.1001/jamainternmed.2020.0040
- Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group.Ann Intern Med. 2019; 171: 805-822https://doi.org/10.7326/M19-1795
- 2020 ACC Expert Consensus Decision Pathway on management of bleeding in patients on oral anticoagulants.J Am Coll Cardiol. 2020; 76: 594-622
Frost J, Campos-Outcalt D, Hoelting D, et al. Pharmacologic management of newly detected atrial fibrillation updated clinical practice guideline; Updated Clinical Practice Guideline 2017. Available at: https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/atrial-fibrillation.html. Accessed October 26, 2021.
Funding: JEK received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant, K23DK 11879 . SDS, LL, Y-XY, and JEK received funding for study 1 I01HX002693-01 from the Veterans Affairs Health System .
Conflicts of Interest: GB reports consulting fees from Pfizer/Bristol-Myers Squibb, Janssen and AcelisConnected Health. NS reports consulting fees from Alexion Pharmaceuticals. LL reports consulting fees from Phathom Pharmaceuticals. JEK, AF, JJG, DH, SDS, Y-XY, and JS report none.
Authorship: All authors had access to the data and a role in writing this manuscript.